Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

ClinicalTrials.gov ID: NCT02141854

Public ClinicalTrials.gov record NCT02141854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.

Study identification

NCT ID
NCT02141854
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
882 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2014
Primary completion
Aug 31, 2015
Completion
Aug 31, 2015
Last update posted
Nov 8, 2021

2014 – 2015

United States locations

U.S. sites
85
U.S. states
33
U.S. cities
77
Facility City State ZIP Site status
Teva Investigational Site 12429 Birmingham Alabama
Teva Investigational Site 12599 Little Rock Alaska
Teva Investigational Site 12609 Phoenix Arizona
Teva Investigational Site 12445 Costa Mesa California
Teva Investigational Site 12454 Encinitas California
Teva Investigational Site 12456 Fresno California
Teva Investigational Site 12461 Fullerton California
Teva Investigational Site 12410 Huntington Beach California
Teva Investigational Site 12452 Huntington Beach California
Teva Investigational Site 12417 Long Beach California
Teva Investigational Site 13017 Mission Viejo California
Teva Investigational Site 12462 Rancho Mirage California
Teva Investigational Site 12411 Rolling Hills Estates California
Teva Investigational Site 13018 San Diego California
Teva Investigational Site 12413 San Jose California
Teva Investigational Site 12403 Stockton California
Teva Investigational Site 12444 Upland California
Teva Investigational Site 12999 Vista California
Teva Investigational Site 12405 Centennial Colorado
Teva Investigational Site 12419 Centennial Colorado
Teva Investigational Site 13000 Colorado Springs Colorado
Teva Investigational Site 12459 Waterbury Connecticut
Teva Investigational Site 13004 Largo Florida
Teva Investigational Site 12414 Miami Florida
Teva Investigational Site 12437 Miami Florida
Teva Investigational Site 12427 Orlando Florida
Teva Investigational Site 12423 Ormond Beach Florida
Teva Investigational Site 12604 Panama City Florida
Teva Investigational Site 13316 Tamarac Florida
Teva Investigational Site 12606 Winter Park Florida
Teva Investigational Site 12435 Savannah Georgia
Teva Investigational Site 13315 Eagle Idaho
Teva Investigational Site 12439 River Forest Illinois
Teva Investigational Site 12449 Shiloh Illinois
Teva Investigational Site 12457 South Bend Indiana
Teva Investigational Site 12446 Bangor Maine
Teva Investigational Site 12602 Columbia Maryland
Teva Investigational Site 12432 Fall River Massachusetts
Teva Investigational Site 12441 North Dartmouth Massachusetts
Teva Investigational Site 12466 North Dartmouth Massachusetts
Teva Investigational Site 13001 Royal Oak Michigan
Teva Investigational Site 12428 Ypsilanti Michigan
Teva Investigational Site 13020 Minneapolis Minnesota
Teva Investigational Site 12451 Columbia Missouri
Teva Investigational Site 12421 Rolla Missouri
Teva Investigational Site 12412 St Louis Missouri
Teva Investigational Site 12453 St Louis Missouri
Teva Investigational Site 12610 Missoula Montana
Teva Investigational Site 13021 Las Vegas Nevada
Teva Investigational Site 12409 Skillman New Jersey
Teva Investigational Site 12464 Brooklyn New York
Teva Investigational Site 12603 The Bronx New York
Teva Investigational Site 12430 Charlotte North Carolina
Teva Investigational Site 12407 Raleigh North Carolina
Teva Investigational Site 12415 Canton Ohio
Teva Investigational Site 12455 Cincinnati Ohio
Teva Investigational Site 12463 Cincinnati Ohio
Teva Investigational Site 12460 Middleburg Heights Ohio
Teva Investigational Site 12426 Edmond Oklahoma
Teva Investigational Site 13008 Oklahoma City Oklahoma
Teva Investigational Site 12406 Medford Oregon
Teva Investigational Site 12442 Portland Oregon
Teva Investigational Site 12563 Normal Square Pennsylvania
Teva Investigational Site 12443 Pittsburgh Pennsylvania
Teva Investigational Site 12438 Upland Pennsylvania
Teva Investigational Site 12408 Charleston South Carolina
Teva Investigational Site 12431 Greenville South Carolina
Teva Investigational Site 12465 Mt. Pleasant South Carolina
Teva Investigational Site 12467 Mt. Pleasant South Carolina
Teva Investigational Site 12420 Orangeburg South Carolina
Teva Investigational Site 12433 Rock Hill South Carolina
Teva Investigational Site 13003 Knoxville Tennessee
Teva Investigational Site 12425 Arlington Texas
Teva Investigational Site 12416 Dallas Texas
Teva Investigational Site 12418 Dallas Texas
Teva Investigational Site 12440 El Paso Texas
Teva Investigational Site 12447 Killeen Texas
Teva Investigational Site 13318 San Antonio Texas
Teva Investigational Site 13002 Sugar Land Texas
Teva Investigational Site 12424 Waco Texas
Teva Investigational Site 12422 South Burlington Vermont
Teva Investigational Site 12605 Richmond Virginia
Teva Investigational Site 12436 Spokane Washington
Teva Investigational Site 12564 Tacoma Washington
Teva Investigational Site 12448 Greenfield Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02141854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02141854 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →